Kymera Therapeutics KYMR Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's change in deferred revenue?
- Kymera Therapeutics (KYMR) reported change in deferred revenue of -$34.37M in Q1 2026.
- How has Kymera Therapeutics's change in deferred revenue changed year-over-year?
- Kymera Therapeutics's change in deferred revenue decreased by 1536.4% year-over-year, from -$2.1M to -$34.37M.
- What is the long-term trend for Kymera Therapeutics's change in deferred revenue?
- Over 2 years (2021 to 2024), Kymera Therapeutics's change in deferred revenue has grown at a -23.0% compound annual growth rate (CAGR), from -$69.36M to -$41.08M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.